From the Journals

MRI matches standard biopsy at detecting significant prostate cancers


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE


“We found that a diagnostic pathway including risk assessment with MRI before biopsy and MRI-targeted biopsy in the presence of a lesion suggestive of cancer was superior to the diagnostic pathway of standard transrectal ultrasonography-guided biopsy,” Dr. Kasivisvanathan and his associates concluded.

The study was supported by awards to Dr. Kasivisvanathan from the U.K. National Institute for Health Research and by the European Association of Urology Research Foundation. He reported no other significant conflicts of interest to disclose.

SOURCE: Kasivisvanathan V et al. N Engl J Med. 2018 Mar 19. doi: 10.1056/NEJMoa1801993.

Pages

Recommended Reading

Axitinib/pembrolizumab combo safe, effective against mRCC
MDedge Hematology and Oncology
Checkpoint inhibitors forge new treatment paradigm for metastatic bladder cancer
MDedge Hematology and Oncology
Prostate cancer survival similar with EBRT/brachytherapy or surgery, analysts claim
MDedge Hematology and Oncology
Avelumab safety compares with other checkpoint inhibitors
MDedge Hematology and Oncology
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Hematology and Oncology
Excellent prognosis for cystic RCC evaluated with radiologic threshold of greater than 50%
MDedge Hematology and Oncology
DNA repair gene mutations predict response to anti–PD-1/PD-L1 in urothelial cancer
MDedge Hematology and Oncology
Emerging data help inform immunotherapy for urothelial cancer
MDedge Hematology and Oncology
Dose-escalated radiation therapy brings mixed results in prostate cancer
MDedge Hematology and Oncology
Protons linked to lower urinary AEs, higher costs than with IMRT for prostate cancer
MDedge Hematology and Oncology